nach oben

01.11.2015 | Review Article - Review Health Services | Ausgabe 11/2015

Polymyalgia rheumatica: strategies for efficient practice and quality assurance

Zeitschrift:: Rheumatology International > Ausgabe 11/2015

Autoren:: Michael Schirmer, Christian Dejaco, Bhaskar Dasgupta, Eric L. Matteson

Abstract

Polymyalgia rheumatica (PMR) is the most common inflammatory rheumatic disease in persons over the age of 50 years. There are many diseases which mimic PMR, for which reason a careful diagnostic approach is required. While it is thought to be exquisitely responsive to glucocorticosteroid therapy, many patients respond incompletely and/or develop serious side effects over the protracted disease course. Improved methods for classification and disease assessment together with standardized treatment approaches and outcome assessments can serve to improve the care of patients with this disease.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Jetzt einloggen Kostenlos registrieren

★ PREMIUM-INHALT

e.Med Interdisziplinär

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag als Mediziner

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Alle e.Med Abos bis 30. April 2021 zum halben Preis!

Jetzt gratis testen * Jetzt kaufen

Sie können e.Med Interdisziplinär 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

Alle e.Med Abos bis 30. April 2021 zum halben Preis!

Jetzt e.Med zum Sonderpreis bestellen!

Jetzt testen ¹

Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, National Deyo RA, Workgroup Arthritis Data et al (2008) Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 58(1):26–35 PubMedCentralCrossRefPubMed

Doran MF, Crowson CS, O’Fallon WM, Hunder GG, Gabriel SE (2002) Trends in the incidence of polymyalgia rheumatica over a 30 year period in Olmsted County, Minnesota, USA. J Rheumatol 29:1694–1697 PubMed

Weyand CM, Fulbright JW, Evans JM, Hunder GG, Goronzy JJ (1999) Corticosteroid requirements in polymyalgia rheumatica. Arch Int Med 159(6):577–584 CrossRef

Matteson EL, Maradit-Kremers H, Cimmino MA, Schmidt WA, Schirmer M, Salvarani C et al (2012) Patient reported outcomes in polymyalgia rheumatica. J Rheumatol 39(4):795–803 CrossRefPubMed

Hutchings A, Hollywood J, Lamping DL, Pease CT, Chakravarty K, Silverman B et al (2007) Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica. Arthritis Rheum 57(5):803–809 CrossRefPubMed

Dasgupta B, Cimmino MA, Maradit-Kremers H, Schmidt WA, Schirmer M, Salvarani C et al (2012) European League Against Rheumatism/American College of Rheumatology provisional classification criteria for polymyalgia rheumatica. Ann Rheum Dis 71:484–492 PubMedCentralCrossRefPubMed

Maradit-Kremers H, Dasgupta B, Matteson EL (2009) Polymyalgia rheumatica. In: Preedy VR, Watson RR (eds) Handbook of disease burdens and quality of life measures. Springer, Berlin, pp 3996–4012

BSR and BHPR Standards, Guidelines and Audit Working Group, Dasgupta B, Borg FA, Hassan N, Barraclough K, Bourke B, Fulcher J et al (2010) BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology (Oxford) 49(1):186–190 CrossRef

Dasgupta B, Matteson EL, Maradit-Kremers H (2007) Management guidelines and outcome measures in polymyalgia rheumatica (PMR). Clin Exp Rheumatol 25(suppl 47):S130–S136

10.

ACR/EULAR PMR Guidelines Development Group, Dejaco C, Singh Y, Perel P, Hutchings A, Matteson EL, Dasgupta B (2014) Current evidence for therapeutic interventions in polymyalgia rheumatica (PMR): a systematic literature review informing the ACR/EULAR recommendations for the management of PMR. Ann Rheum Dis 73(suppl2):552

11.

Salvarani C, Cantini F, Boiardi L, Hunder GG (2002) Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 347(4):261–271 CrossRefPubMed

12.

Weyand CM, Goronzy JJ (2014) Clinical practice. Giant-cell arteritis and polymyalgia rheumatica. N Engl J Med 371(1):50–57 PubMedCentralCrossRefPubMed

13.

Gonzalez-Gay MA, Garcia-Porrua C, Salvarani C, Olivieri I, Hunder GG (2000) The spectrum of conditions mimicking polymyalgia rheumatica in Northwestern Spain. J Rheumatol 27:2179–2184 PubMed

14.

Macchioni P, Catanoso MG, Pipitone N, Boiardi L, Salvarani C (2009) Longitudinal examination with shoulder ultrasound of patients with polymyalgia rheumatica. Rheumatology (Oxford) 48(12):1566–1569 CrossRef

15.

De Miguel E, Roxo A, Castillo C, Peiteado D, Villalba A, Martin-Mola E (2012) The utility and sensitivity of colour Doppler ultrasound in monitoring changes in giant cell arteritis. Clin Exp Rheumatol 30(1 Suppl 70):S34–S38 PubMed

16.

Schmidt WA (2013) Polymyalgia rheumatica. Z Rheumatol 72(1):59–65 CrossRefPubMed

17.

Dasgupta B, Dolan AL, Panayi GS, Fernandes L (1998) An initially double-blind controlled 96 week trial of depot methylprednisolone against oral prednisolone in the treatment of polymyalgia rheumatica. Br J Rheumatol 37(2):189–195 CrossRefPubMed

18.

Kyle V, Hazleman BL (1993) The clinical and laboratory course of polymyalgia rheumatica/giant cell arteritis after the first 2 months of treatment. Ann Rheum Dis 52(12):847–850 PubMedCentralCrossRefPubMed

19.

Hernández-Rodríguez J, Cid MC, López-Soto A, Espigol-Frigolé G, Bosch X (2009) Treatment of polymyalgia rheumatica: a systematic review. Arch Intern Med 169(20):1839–1850 CrossRefPubMed

20.

Maradit Kremers HM, Reinalda MS, Crowson CS, Zinsmeister AR, Hunder GG, Gabriel SE (2005) Relapse in a population based cohort of patients with polymyalgia rheumatica. J Rheumatol 32(1):65–73

21.

Mackie SL, Hensor EM, Haugeberg G, Bhakta B, Pease CT (2010) Can the prognosis of polymyalgia rheumatica be predicted at disease onset? Results from a 5-year prospective study. Rheumatology (Oxford) 49:716–722 CrossRef

22.

Myklebust G, Gran JT (2001) Prednisolone maintenance dose in relation to starting dose in the treatment of polymyalgia rheumatica and temporal arteritis. A prospective 2-year study in 273 patients. Scand J Rheumatol 30:260–267 CrossRefPubMed

23.

Maradit Kremers H, Reinalda MS, Crowson CS, Zinsmeister AR, Hunder GG, Gabriel SE (2005) Use of physician services in a population-based cohort of patients with polymyalgia rheumatica over the course of their disease. Arthr Care Res 53(3):395–403 CrossRef

24.

Kremers HM, Reinalda MS, Crowson CS, Zinsmeister AR, Hunder GG, Gabriel SE (2005) Direct medical costs of polymyalgia rheumatica. Arthritis Rheum 53(4):578–584 CrossRefPubMed

25.

Caporali R, Cimmino MA, Ferraccioli G, Gerli R, Klersy C, Salvarani C et al (2004) Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 141(7):493–500 CrossRefPubMed

26.

Ferraccioli G, Salaffi F, De Vita S, Casatta L, Bartoli E (1996) Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study. J Rheumatol 23(4):624–628 PubMed

27.

van der Veen MJ, Dinant HJ, van Booma-Frankfort C, van Albada-Kuipers GA, Bijlsma JW (1996) Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann Rheum Dis 55(4):218–223 PubMedCentralCrossRefPubMed

28.

Gabriel SE, Sunku J, Salvarani C, O’Fallon WM, Hunder GG (1997) Adverse outcomes of anti-inflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum 40(10):1873–1878 CrossRefPubMed

29.

Cleuziou C, Binard A, De Bandt M, Berthelot JM, Saraux A (2012) Contribution of the polymyalgia rheumatica activity score to glucocorticoid dosage adjustment in everyday practice. J Rheumatol 39(2):310–313 CrossRefPubMed

30.

Macchioni P, Boiardi L, Catanoso M, Pazzola G, Salvarani C (2014) Performance of the new 2012 EULAR/ACR classification criteria for polymyalgia rheumatica: comparison with the previous criteria in a single-centre study. Ann Rheum Dis 73(6):1190–1193 CrossRefPubMed

31.

Mackie SL, Arat S, da Silva J, Duarte C, Halliday S, Hughes R et al (2014) Polymyalgia Rheumatica (PMR) Special Interest Group at OMERACT 11: outcomes of importance for patients with PMR. J Rheumatol 41(4):819–823 CrossRefPubMed

32.

Leeb BF, Rintelen B, Sautner J, Fassl C, Bird HA (2007) The polymyalgia rheumatica activity score in daily use: proposal for a definition of remission. Arthritis Rheum 57(5):810–815 CrossRefPubMed

33.

Inflammatory Joint Disease Working Group of the French Society for Rheumatology, Binard A, de Bandt M, Berthelot JM, Saraux A (2008) Performance of the polymyalgia rheumatica activity score for diagnosing disease flares. Arthritis Rheum 59(2):263–269 CrossRef

34.

Bahlas S, Ramos-Remus C, Davis P (2000) Utilisation and costs of investigations, and accuracy of diagnosis of polymyalgia rheumatica by family physicians. Clin Exp Rheumatol 19:278–280 CrossRef

35.

Dejaco C, Duftner C, Cimmino MA, Dasgupta B, Salvarani C, Crowson CS et al (2011) Definition of remission and relapse in polymyalgia rheumatica—data from a literature search compared to a Delphi based expert consensus. Ann Rheum Dis 70(3):447–453 PubMedCentralCrossRefPubMed

36.

Kalke S, Mukerjee D, Dasgupta B (2000) A study of the health assessment questionnaire to evaluate functional status in polymyalgia rheumatica. Rheumatology (Oxford) 39(8):883–885 CrossRef

37.

Gran JT, Myklebust G, Wilsgaard T, Jacobsen BK (2001) Survival in polymyalgia rheumatica and temporal arteritis: a study of 398 cases and matched population controls. Rheumatology (Oxford) 40(11):1238–1242 CrossRefPubMed

Titel: Polymyalgia rheumatica: strategies for efficient practice and quality assurance
Autoren:: Michael Schirmer
Christian Dejaco
Bhaskar Dasgupta
Eric L. Matteson
Publikationsdatum: 01.11.2015
DOI: https://doi.org/10.1007/s00296-015-3297-y
Verlag: Springer Berlin Heidelberg
Zeitschrift: Rheumatology International Clinical and Experimental Investigations
Ausgabe 11/2015
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X

Sie können e.Med Innere Medizin 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

Neu im Fachgebiet Innere Medizin

09.04.2021 | Supraventrikuläre Tachykardien | Nachrichten

Newsletter bestellen

Bildnachweise

Mail Icon II

Springer Medizin

Polymyalgia rheumatica: strategies for efficient practice and quality assurance

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Alle e.Med Abos bis 30. April 2021 zum halben Preis!

e.Med Innere Medizin

Alle e.Med Abos bis 30. April 2021 zum halben Preis!

Neu im Fachgebiet Innere Medizin

Troponinwert fehlinterpretiert – Patient hat den Schaden

Deutlich mehr Kinder infiziert als vermutet

Thromboserisiko bei ambulanten COVID-Patienten nicht erhöht

So sollten Ärzte bei Allergie-Patienten vor der COVID-19-Impfung vorgehen

Newsletter

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Alle e.Med Abos bis 30. April 2021 zum halben Preis!

e.Med Innere Medizin

Alle e.Med Abos bis 30. April 2021 zum halben Preis!

Weitere Artikel der Ausgabe 11/2015

Colchicine–clarithromycin-induced rhabdomyolysis in Familial Mediterranean Fever patients under treatment for Helicobacter pylori

Decreased physical activity and cardiorespiratory fitness in adults with ankylosing spondylitis: a cross-sectional controlled study

Direct medical costs and their predictors in South Korean patients with systemic lupus erythematosus

Effects of rheumatoid arthritis on household chores and leisure-time activities

Influence of rheumatoid arthritis-related morning stiffness on productivity at work: results from a survey in 11 European countries

Evaluation of functional capacity in individuals with signs and symptoms of musculoskeletal disease: results of the BRAZCO population study (Brazilian COPCORD Study)

Neu im Fachgebiet Innere Medizin

Troponinwert fehlinterpretiert – Patient hat den Schaden

Deutlich mehr Kinder infiziert als vermutet

Thromboserisiko bei ambulanten COVID-Patienten nicht erhöht

So sollten Ärzte bei Allergie-Patienten vor der COVID-19-Impfung vorgehen

Newsletter